Encyclopedia  /  Treatments  /  Brexanolone (Zulresso)
Treatment

Brexanolone (Zulresso)

Brexanolone (Zulresso) was the first drug ever FDA-approved specifically for postpartum depression (2019). Given as a 60-hour IV infusion in a certified healthcare setting, it can lift moderate-to-severe PPD within days by acting on the brain’s GABA system.
Educational information, not medical advice. This page summarizes published research and public-health guidance for learning purposes. It is not a substitute for diagnosis or treatment by a qualified clinician. If you are struggling, talk to your doctor or midwife. In a crisis, call or text 988 or the Maternal Mental Health Hotline at 1-833-852-6262.

Evidence snapshot — computed from live data

174
Studies indexed (PubMed)
0+
Active trials
moderate evidence
Strength score 56/100

What makes it different

Unlike SSRIs, brexanolone is a neuroactive steroid that mimics allopregnanolone—a hormone that plummets after birth. It works rapidly, often within the 60-hour infusion, rather than over weeks.

How it’s given

It requires continuous IV infusion over about 2.5 days at a certified center with monitoring, because of the risk of excessive sedation. This intensity limits its use to specific moderate-to-severe cases.

See how this fits alongside other options in our treatment overview, and the medications used for PPD in the medication guide.

Sources & further reading

Selected recent peer-reviewed studies, pulled live from the U.S. National Library of Medicine (PubMed). Counts and citations update automatically.

  1. Dargan TL et al. “Potential of Neurosteroids for Precision Medicine in Psychiatry.” Biological psychiatry (2026). PubMed →
  2. Xie G et al. “Real-world adverse event profiles of Zuranolone and Brexanolone based on FAERS and VigiAccess databases: An observational study.” Medicine (2026). PubMed →
  3. Xiao Y et al. “Comparative efficacy and acceptability of pharmacological interventions for postpartum depression: a systematic review and network meta-analysis.” Psychiatry research (2026). PubMed →
  4. Ok HI et al. “First Reported Case of Dissociative Symptoms Associated With Zuranolone Use in Peripartum Depression.” Cureus (2026). PubMed →
  5. Lyu G et al. “Innovations in Depression Diagnosis and Treatment: A Review of Biological, Cognitive, and Psychosocial Advances.” Current topics in medicinal chemistry (2026). PubMed →
Explore the encyclopedia

Related entries

Common questions

Frequently asked

How fast does brexanolone work?

Many women see improvement during or shortly after the 60-hour infusion—far faster than standard antidepressants.

Why isn’t it used more often?

It requires a monitored IV infusion at a certified facility, which makes it less accessible than the newer oral option, zuranolone.

Emily Montague, The Postpartum Chef
Written & reviewed by

Emily Montague, The Postpartum Chef

Emily is a chef, mother of five and postpartum-recovery educator who revives the 2,000-year-old zuo yuezi ("sitting month") tradition for modern mothers. Her patent-backed, food-first method helps women rebuild after birth and ease postpartum depression — and she now certifies doulas and midwives to cook it for their own clients.

Visit The Sitting Month →    Meet Emily →

Ready to heal the first 28 days?

Emily's food-first recovery course, recovery teas and doula & midwife certification live at The Sitting Month. Text Emily and she'll help you find the right starting point.

Explore The Sitting Month